Pentwater Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Pentwater Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,000	Closed	-$986K	–	123
2023 Q4	$986K	Hold	100,000	–	–	0.01%	95
2023 Q3	$765K	Sell	100,000 -265,000	-73%	-$2.64M	﹤0.01%	105
2023 Q2	$2.73M	Sell	365,000 -55,000	-13%	-$385K	0.02%	87
2023 Q1	$2.8M	Buy	420,000 +20,000	+5%	+$159K	0.03%	100
2022 Q4	$3.08M	Buy	400,000 +100,000	+33%	+$981K	0.05%	77
2022 Q3	$3.19M	Hold	300,000	–	–	0.04%	100
2022 Q2	$2.44M	Hold	300,000	–	–	0.03%	123
2022 Q1	$2.15M	Buy	300,000 +20,000	+7%	+$213K	0.03%	108
2021 Q4	$4.8M	Buy	280,000 +15,000	+6%	+$282K	0.05%	97
2021 Q3	$6.1M	Buy	265,000 +12,500	+5%	+$354K	0.06%	98
2021 Q2	$9.22M	Buy	+252,500	New	+$7.47M	0.08%	80

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pentwater Capital Management's RXRX Position: Q1 2024 in Review

Pentwater Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2024, closing a stake of 100,000 shares — an estimated $986K sold.

Pentwater Capital Management first reported a position in RXRX in Q2 2021 and held it in 11 quarters. The position peaked at $9.22M in Q2 2021. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

Pentwater Capital Management reported no remaining Recursion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Pentwater Capital Management sold 100,000 Recursion Pharmaceuticals shares in Q1 2024, an estimated $986K.
Pentwater Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 11 quarters.
Pentwater Capital Management's Recursion Pharmaceuticals position peaked at $9.22M in Q2 2021.
249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on Pentwater Capital Management's 13F filing for Q1 2024, filed 15 May 2024.